Long term safety and visibility of a novel liquid fiducial marker foruse in image guided radiotherapy of non-small cell lung cancer

Steen Riisgaard de Blanck*, Jonas Scherman Rydhög, Klaus Richter Larsen, Paul Frost Clementsen, Mirjana Josipovic, Marianne Camille Aznar, Per Munck af Rosenschöld, Rasmus Irming Jølck, Lena Specht, Thomas Lars Andresen, Gitte Fredberg Persson

*Corresponding author for this work

    Research output: Contribution to journalJournal articleResearchpeer-review

    236 Downloads (Pure)

    Abstract

    Safety and clinical feasibility of injecting a novel liquid fiducial marker for use in image guided radiotherapy in 15 patients with non-small cell lung cancer are reported. No major safety or toxicity issues were encountered. Markers present at start of radiotherapy remained visible in cone beam computed tomography and fluoroscopy images throughout the treatment course and on computed tomography images during follow-up (0–38 months). Marker volume reduction was seen until 9 months after treatment, after which no further marker breakdown was found. No post-treatment migration or marker related complications were found.
    Original languageEnglish
    JournalClinical and Translational Radiation Oncology
    Volume13
    Pages (from-to)24-28
    ISSN2405-6308
    DOIs
    Publication statusPublished - 2018

    Keywords

    • Liquid fiducial marker
    • Image-guided radiotherapy
    • NSCLC
    • Endoscopic ultrasound
    • EBUS

    Fingerprint Dive into the research topics of 'Long term safety and visibility of a novel liquid fiducial marker foruse in image guided radiotherapy of non-small cell lung cancer'. Together they form a unique fingerprint.

    Cite this